Compare Goodyear Tire & Rubber Co (GT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Goodyear Tire & Rubber Co trades at $4.78 (market cap $1.35B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 94.9× Goodyear Tire & Rubber Co's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| GT | VRTX | |
|---|---|---|
Market Cap | $1.35B | $128.16B |
Volume | 6,504,242 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $557.96 |
52-Week Low | $4.66 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | $8.70B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GT trades at $4.75, down 1.93% in the last 24 hours, near its 52-week low. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $1.72B in 2025, with negative profit margins and declining revenue, though cash flow from operations improved to $796M. Recent news highlights restructuring efforts and a 'shrink-to-grow' strategy to boost margins.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests upside with a $8.00 price target. Key risks include execution of the turnaround plan, competitive pressures, and macroeconomic headwinds. Institutional sentiment is mixed, with 34.6% of analysts rating it a buy.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
